![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BOEHRINGER INGELHEIM PHARMA TO ACQUIRE ZANTAC FROM JOHNSON & JOHNSON AND PFIZER CONSUMER HEALTHCARE BUSINESS
BOEHRINGER INGELHEIM PHARMA TO ACQUIRE ZANTAC FROM JOHNSON & JOHNSON AND PFIZER CONSUMER HEALTHCARE BUSINESS
Boehringer Ingelheim Pharmaceuticals Inc. said Thursday it has entered into an agreement with Johnson & Johnson and Pfizer Inc. to acquire the U.S. rights to the over-the-counter Zantac product line for $509.5 million in cash. Trading Markets (http://www.tradingmarkets.com/.site/news/BREAKING%20NEWS/455932/)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct